Cargando…

Reciprocal positive selection for weakness - preventing olaparib resistance by inhibiting BRCA2

Human tumor heterogeneity promotes therapeutic failure by increasing the likelihood of resistant cell subpopulations. The PARP-1 inhibitor olaparib is approved for use in BRCA-mutated ovarian cancers but BRCA2-reversion mutations lead to functional homologous recombination repair (HRR) and olaparib...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rytelewski, Mateusz, Vareki, Saman Maleki, Mangala, Lingegowda S., Romanow, Larissa, Jiang, Dahai, Pradeep, Sunila, Rodriguez-Aguayo, Christian, Lopez-Berestein, Gabriel, Figueredo, Rene, Ferguson, Peter J., Vincent, Mark, Sood, Anil K., Koropatnick, James D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4991495/ https://www.ncbi.nlm.nih.gov/pubmed/26959114 http://dx.doi.org/10.18632/oncotarget.7883

Ejemplares similares

Inhibition of BRCA2 and Thymidylate Synthase Creates Multidrug Sensitive Tumor Cells via the Induction of Combined “Complementary Lethality”
por: Rytelewski, Mateusz, et al.
Publicado: (2013)

Indoleamine 2,3-dioxygenase mediates immune-independent human tumor cell resistance to olaparib, gamma radiation, and cisplatin
por: Vareki, Saman Maleki, et al.
Publicado: (2014)

siRNA knockdown of mitochondrial thymidine kinase 2 (TK2) sensitizes human tumor cells to gemcitabine
por: Di Cresce, Christine, et al.
Publicado: (2015)

IDO Downregulation Induces Sensitivity to Pemetrexed, Gemcitabine, FK866, and Methoxyamine in Human Cancer Cells
por: Maleki Vareki, Saman, et al.
Publicado: (2015)

Therapeutic evaluation of microRNA-15a and microRNA-16 in ovarian cancer
por: Dhar Dwivedi, Shailendra Kumar, et al.
Publicado: (2016)

COTI-2, a novel small molecule that is active against multiple human cancer cell lines in vitro and in vivo
por: Salim, Kowthar Y., et al.
Publicado: (2016)

Novel anti-cancer drug COTI-2 synergizes with therapeutic agents and does not induce resistance or exhibit cross-resistance in human cancer cell lines
por: Maleki Vareki, Saman, et al.
Publicado: (2018)

Olaparib and somatic BRCA mutations
por: George, Angela, et al.
Publicado: (2017)

Correction: COTI-2, a novel small molecule that is active against multiple human cancer cell lines in vitro and in vivo
por: Salim, Kowthar Y., et al.
Publicado: (2017)

Targeting the centriolar replication factor STIL synergizes with DNA damaging agents for treatment of ovarian cancer
por: Rabinowicz, Noa, et al.
Publicado: (2017)

High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors
por: Maleki Vareki, Saman
Publicado: (2018)

Treatment-naïve HPV+ head and neck cancers display a T-cell-inflamed phenotype distinct from their HPV- counterparts that has implications for immunotherapy
por: Gameiro, Steven F., et al.
Publicado: (2018)

The Effect of the Gut Microbiota on Systemic and Anti-Tumor Immunity and Response to Systemic Therapy against Cancer
por: Aghamajidi, Azin, et al.
Publicado: (2022)

Calcium Dependent FAK/CREB/TNNC1 Signaling Mediates the Effect of Stromal MFAP5 on Ovarian Cancer Metastatic Potential
por: Leung, Cecilia S., et al.
Publicado: (2014)

Olaparib treatment for BRCA-mutant ovarian cancer with leptomeningeal disease
por: Bangham, Madeleine, et al.
Publicado: (2016)

Zebrafish Xenografts Unveil Sensitivity to Olaparib beyond BRCA Status
por: Varanda, Ana Beatriz, et al.
Publicado: (2020)

BRCA2 reversion mutation confers resistance to olaparib in breast cancer
por: Yamamoto, Shinya, et al.
Publicado: (2023)

Immunosuppressive Effects of Myeloid-Derived Suppressor Cells in Cancer and Immunotherapy
por: Krishnamoorthy, Mithunah, et al.
Publicado: (2021)

Addressing the Elephant in the Immunotherapy Room: Effector T-Cell Priming versus Depletion of Regulatory T-Cells by Anti-CTLA-4 Therapy
por: Hong, Megan M Y, et al.
Publicado: (2022)

The role of gut microbiome in immune modulation in metastatic renal cell carcinoma
por: Deluce, Jasna, et al.
Publicado: (2022)

Olaparib is effective for recurrent urothelial carcinoma with BRCA2 pathogenic germline mutation: first report on olaparib response in recurrent UC
por: Yang, Hong, et al.
Publicado: (2020)

PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis
por: Rodriguez-Aguayo, Cristian, et al.
Publicado: (2019)

Corrigendum to “PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis” [EBioMedicine 40 (2019) 290-304]
por: Rodriguez-Aguayo, Cristian, et al.
Publicado: (2022)

Olaparib Combined with an ATR or Chk1 Inhibitor as a Treatment Strategy for Acquired Olaparib-Resistant BRCA1 Mutant Ovarian Cells
por: Burgess, Brian T., et al.
Publicado: (2020)

Neoadjuvant Immunotherapy for High-Risk, Resectable Malignancies: Scientific Rationale and Clinical Challenges
por: Krishnamoorthy, Mithunah, et al.
Publicado: (2021)

Hypoxia-upregulated microRNA-630 targets Dicer, leading to increased tumor progression
por: Rupaimoole, Rajesha, et al.
Publicado: (2016)

Response of BRCA1-mutated gallbladder cancer to olaparib: A case report
por: Xie, Yuan, et al.
Publicado: (2016)

MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib
por: Whicker, Margaret E., et al.
Publicado: (2016)

Metabolic shifts toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian cancer
por: Yang, Lifeng, et al.
Publicado: (2014)

TFEB ameliorates the impairment of the autophagy-lysosome pathway in neurons induced by doxorubicin
por: Moruno Manchon, Jose Felix, et al.
Publicado: (2016)

Inactivating Mutations of the IK Gene Weaken Ku80/Ku70-Mediated DNA Repair and Sensitize Endometrial Cancer to Chemotherapy
por: Gao, Chao, et al.
Publicado: (2021)

Combinations of ATR, Chk1 and Wee1 Inhibitors with Olaparib Are Active in Olaparib Resistant Brca1 Proficient and Deficient Murine Ovarian Cells
por: Chiappa, Michela, et al.
Publicado: (2022)

Therapeutic efficacy of liposomal Grb2 antisense oligodeoxynucleotide (L-Grb2) in preclinical models of ovarian and uterine cancer
por: Lara, Olivia D., et al.
Publicado: (2020)

Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy
por: Lorusso, Domenica, et al.
Publicado: (2018)

Metastatic Breast Cancer with BRCA Mutation Discovered By Next-Generation Sequencing Responding to Olaparib
por: Rizvi, Wajeeha, et al.
Publicado: (2017)

Pancreatic cancer patients with germline BRCA mutations can benefit from olaparib treatment
por: Mukherjee, Shibani, et al.
Publicado: (2020)

Olaparib Treatment in a Patient with Advanced Gallbladder Cancer Harboring BRCA1 Mutation
por: Li, Xiaofen, et al.
Publicado: (2021)

Case report: olaparib use in metastatic lung adenocarcinoma with BRCA2 pathogenic variant
por: Soon Jian Hao, Jonathan, et al.
Publicado: (2022)

Two cases of CRPC with BRCA mutation treated by olaparib after favorable response to cisplatin
por: Miyazawa, Yoshiyuki, et al.
Publicado: (2022)

Olaparib-Resistant BRCA2(MUT) Ovarian Cancer Cells with Restored BRCA2 Abrogate Olaparib-Induced DNA Damage and G2/M Arrest Controlled by the ATR/CHK1 Pathway for Survival
por: Biegała, Łukasz, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_knko7sataosrirbke18pj2e699